Preloading With Nicotine Replacement Therapy in People With HIV Who Smoke: A Pilot Randomized Controlled Trial
Nicotine and Tobacco Research · 2025
DOI: 10.1093/ntr/ntaf123 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Patricia A Cioe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI. Hauptthemen laut MEDLINE: Smoking Cessation, HIV Infections, Tobacco Use Cessation Devices, Smoking. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Cancer Institute of the National Institutes of Health.
Abstract (Originalsprache)
Introduction
Smoking cessation rates in people with HIV (PWH) are lower than in the general population, even when evidence-based treatments are used. This 16-week study examined the feasibility, acceptability, and preliminary efficacy of preloading with nicotine replacement therapy (NRT) in PWH to improve cessation outcomes.
Methods
Forty-nine participants were randomized to nicotine patch preloading (NRT-P) for 3 weeks prior to the target quit date (TQD) or standard treatment with no preloading (ST). All participants received combination NRT for 8 weeks at TQD, with five sessions of behavioral counseling. At week 16, biochemically verified 7-day point-prevalence abstinence was assessed.
Results
Mean preloading patch days was 19.7 (out of 21 days; SD 2.7), indicating excellent acceptability. Mean patch days post-TQD (out of 56 days) was 47.4 (SD = 13.2) in NRT-P and 32.7 (SD = 21.8) in ST (t = −2.48, p = .01). At week 16 there was no group difference in week 16 point-prevalence abstinence, but NRT-P participants smoked significantly fewer cigarettes per week (10.1 [SD 14.7] vs. 47.2 [SD 67.6]) and had lower carbon monoxide levels (5.22 [SD 3.6] vs. 10.89 [SD 11.3], p = .04) compared to ST participants. Cessation self-efficacy increased significantly over time in the NRT-P condition only.
Conclusions
NRT preloading is feasible and acceptable among PWH, with excellent adherence to preloading, and benefits observed relative to ST following TQD in patch adherence, self-efficacy, cigarettes smoked per day, and carbon monoxide levels. The lack of effect of preloading on smoking abstinence suggests further study is needed.
Implications
Preloading with nicotine patch among PWH who smoke prior to the TQD may be an effective means of improving adherence to smoking cessation medications both pre- and post-quit. By increasing self-efficacy for quitting and lowering cigarette dependence, preloading may improve cessation rates and help reduce the burden of tobacco-related disease among PWH. Further research is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI.
- Center for Tobacco Research and Intervention, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Cancer Institute of the National Institutes of Health
Zitieren
APA
Cioe, P. A., Stang, G. S., Azam, D., Piper, M. E., & Kahler, C. W. (2025). Preloading With Nicotine Replacement Therapy in People With HIV Who Smoke: A Pilot Randomized Controlled Trial. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntaf123
Vancouver
Cioe PA, Stang GS, Azam D, Piper ME, Kahler CW. Preloading With Nicotine Replacement Therapy in People With HIV Who Smoke: A Pilot Randomized Controlled Trial. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntaf123
BibTeX
@article{Cioe2025,
author = {Cioe, Patricia A and Stang, Garrett S and Azam, Danish and Piper, Megan E and Kahler, Christopher W},
title = {Preloading With Nicotine Replacement Therapy in People With HIV Who Smoke: A Pilot Randomized Controlled Trial},
journal = {Nicotine and Tobacco Research},
year = {2025},
doi = {10.1093/ntr/ntaf123}
}
EUVIMED